A Molecular Take on Malignant Rhabdoid Tumors.
The molecular basis for the clinical heterogeneity observed in patients with malignant rhabdoid tumors is unknown. Recently, two reports revealed molecular inter-tumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs) using genomic, transcriptomic and epigenomic profiling. Distinct molecular subgroups were identified and new therapeutic targets were revealed.
Department of Genomic Medicine, Computational Biology, UT MD Anderson Cancer Center, Houston, TX 77030, USA.
Ming
M
Tang
Department of Genomic Medicine, Computational Biology, UT MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Bioinformatics, Computational Biology, UT MD Anderson Cancer Center, Houston, TX 77030, USA.
Roel Gw
RG
Verhaak
malignant rhabdoid tumors; molecular analysis; pediatric cancer; sequencing
Oncol Rep. 2008 Mar;19(3):819-23
18288421
Nat Rev Genet. 2016 May;17(5):284-99
26972587
Cancer Cell. 2016 Mar 14;29(3):270-84
26977879
Cell. 2015 Jun 18;161(7):1681-96
26091043
Cell. 2016 Jan 28;164(3):550-63
26824661
Cancer Cell. 2016 Mar 14;29(3):394-406
26977886
Cancer Res. 2002 Jan 1;62(1):323-8
11782395
J Clin Invest. 2012 Aug;122(8):2983-8
22797305
Cancer Cell. 2016 Mar 14;29(3):379-93
26923874
Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):10165-70
23723349